131 related articles for article (PubMed ID: 28972450)
1. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
Mahalatchimy A; Faulkner A
Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
Cho E; Yoo SL; Kang Y; Lee JH
Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
[TBL] [Abstract][Full Text] [Related]
3. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
4. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
Plagnol AC; Rowley E; Martin P; Livesey F
Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
[TBL] [Abstract][Full Text] [Related]
5. Achieving reimbursement for regenerative medicine products in the USA.
Ginty PJ; Singh PB; Smith D; Hourd P; Williams DJ
Regen Med; 2010 May; 5(3):463-9. PubMed ID: 20455656
[TBL] [Abstract][Full Text] [Related]
6. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Simoens S; Picavet E; Dooms M; Cassiman D; Morel T
Appl Health Econ Health Policy; 2013 Feb; 11(1):1-3. PubMed ID: 23329382
[No Abstract] [Full Text] [Related]
8. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
9. European pharmaceutical pricing and reimbursement conference.
Ehreth J; Williams D
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
[TBL] [Abstract][Full Text] [Related]
10. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
11. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
Rose JB; Williams DJ
Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
[TBL] [Abstract][Full Text] [Related]
12. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement of orphan drugs in Belgium: what (else) matters?
Picavet E; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
[TBL] [Abstract][Full Text] [Related]
14. Governance of conditional reimbursement practices in The Netherlands.
Boon W; Martins L; Koopmanschap M
Health Policy; 2015 Feb; 119(2):180-5. PubMed ID: 25467790
[TBL] [Abstract][Full Text] [Related]
15. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
16. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
17. Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK.
Gardner J; Webster A; Barry J
Regen Med; 2018 Jan; 13(1):29-39. PubMed ID: 29360014
[TBL] [Abstract][Full Text] [Related]
18. Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
Vertès A
Drugs Today (Barc); 2016 Oct; 52(10):577-583. PubMed ID: 27910966
[TBL] [Abstract][Full Text] [Related]
19. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
20. Remote Monitoring of Chronic Diseases: A Landscape Assessment of Policies in Four European Countries.
Rojahn K; Laplante S; Sloand J; Main C; Ibrahim A; Wild J; Sturt N; Areteou T; Johnson KI
PLoS One; 2016; 11(5):e0155738. PubMed ID: 27195764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
